Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Evrysdi | risdiplam | Spinal muscular atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Saxenda | liraglutide | Chronic weight management in adults | Do not reimburse | Complete | ||
| Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Perseris | risperidone | Schizophrenia, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeomin | incobotulinumtoxinA | Chronic sialorrhea associated with neurological disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Breztri Aerosphere | budesonide/ glycopyrronium /formoterol fumarate | chronic obstructive pulmonary disease (COPD) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trikafta | elexacaftor / tezacaftor / ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation | Reimburse with clinical criteria and/or conditions | Complete | ||
| Inqovi | Decitabine-Cedazuridine | Myelodysplastic Syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onureg | azacitidine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 25, 2024